BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients

Tahapan Penelitian : Recruit
Sponsor:
Mitra Pelaksana:
Dr. Cipto Mangunkusumo National General Hospital
No Registry
Tanggal Input Registry : 04-06-2025

24-09-2024
Decreasing total daily dose of insulin (>= 30%)
Increasing of C-peptide level
 
BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients
Effectivity and Safety of Autologous BM-MNC Stem Cell Therapy and Allogenic Umbilical Cord Mesenchymal Stem Cell for Type 2 Diabetes Mellitus Patients
Interventional
Experimental: Autologue bone marrow mononuclear cell Experimental: Umbilical cord mesenchymal stem cell
10
 

Inclusion Criteria:

Type 2 diabetes patients on insulin therapy with or without oral hypoglycemic agents with total daily dose of insulin >= 0,5 unit/kg body weight, Stable HbA1C in the last six months (HbA1c

Exclusion Criteria:

Type 1 diabetes mellitus, eGFR < 45 mL/min/m2 (for BM-MNC), Liver disease (moderate- severe), Active infection, Contrast hypersensitivity (for BM-MNC), History of Malignancy, Acute coronary syndrome in last three months, Coronary arterial diseases with significant stenosis and has not carried out revascularization, Pregnancy (for women subjects)
 
206/UN2.F1/ETIK/2016
Not applicable
Not applicable
dr. Farid Kurniawan, Sp.PD, PhD